Completed NA INTERVENTIONAL 1-arm NCT04240496

Clinical and Genetic Influencing Factors on Clozapine Pharmacokinetics

Clinical and Genetic Influencing Factors on Clozapine Pharmacokinetics in Schizophrenic Patients

Sponsor: University of Monastir

Conditions CYP1A2 Polymorphism CYP2C19 Polymorphism Clozapine Schizophrenia

Interventions Determination of plasma concentration of clozapine/ Genotyping

Updated 4 times since 2020 Last updated: Jan 21, 2020 Started: Oct 17, 2019 Primary completion: Dec 14, 2019 Completion: Dec 14, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04240496, this NA trial focuses on CYP1A2 Polymorphism and CYP2C19 Polymorphism and remains completed. Sponsored by University of Monastir, it has been updated 4 times since 2019, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Feb 2020 — Jan 2021 [monthly]

Completed NA

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Monastir

Data source: University of Monastir

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Monastir, Tunisia